Ore-Ida has launched a new creative platform called "Ore-Ida or Nothing" to highlight its legacy as the inventor of Tater Tots and reinforce its commitment to quality. The campaign features Keegan-Michael Key in various comedic roles, portraying "imi-taters" who unsuccessfully attempt to replicate the original and emphasize that nothing beats Ore-Ida's unparalleled taste and texture. This initiative represents the brand's largest marketing investment to date, comprising 12 unique spots across TV, online, and social media.

Massachusetts Financial Services Co. MA reduced its stake in Pool Corporation by 7.8% in the fourth quarter, selling 44,436 shares and owning 524,800 shares worth $120.05 million. Other institutional investors have also adjusted their holdings, while company insiders have recently both bought and sold shares. Analyst ratings for Pool are mixed, with an average target price of $279.63, and the company recently reported its quarterly earnings, missing consensus estimates.

Massachusetts Financial Services Co. MA significantly increased its stake in Ingersoll Rand Inc. during the fourth quarter, acquiring an additional 1.6 million shares and raising its total holdings to 1.62 million shares valued at $128.58 million. This surge in institutional investment comes amidst recent insider selling and varied analyst ratings, with the company announcing a quarterly dividend and strong Q4 earnings.

Burney Co. significantly reduced its stake in American Tower Corporation (NYSE:AMT) during Q4 2025, selling over 17,000 shares. The company missed Q4 EPS estimates but exceeded revenue expectations and set positive FY2026 guidance. Insider trading shows mixed activity with a director buying shares and the COO selling, while American Tower also increased its quarterly dividend.

The FDA has refused to file Replimune's application for its experimental skin cancer drug, RP1, in combination with Bristol Myers Squibb's Opdivo due to concerns about the study design. This decision impacts Bristol Myers Squibb's immuno-oncology efforts and highlights regulatory scrutiny risks for combination therapies. While not a verdict on Opdivo itself, it suggests potential delays for future indications and emphasizes the importance of robust trial design in partner-driven oncology programs.

ResMed Inc. is a leader in the sleep apnea device market, particularly with its CPAP machines, and its position is bolstered by expanding telehealth and digital health trends. The company's integration of hardware and software creates recurring revenue streams, and strategic acquisitions further diversify its scope. Despite competitive markets and potential reimbursement pressures, analysts remain positive due to ResMed's innovation, market dominance, and resilient manufacturing.

Baillie Gifford & Co., a major institutional investor, has reduced its stake in Cadence Design Systems (NASDAQ:CDNS) by 19.7% in the fourth quarter of 2025. The firm now holds 29,025 shares valued at $9.07 million. This move is significant as Cadence Design Systems is a leading provider of electronic design automation software, and such institutional activity can indicate market sentiment regarding the stock's valuation and growth prospects.

Despite reassurances from Trump's team that current inflation is due to "short-term disruptions," this article suggests three stocks to consider if those predictions are incorrect. The recommended stocks are NextEra Energy, a stable utility with dividend growth; Vertex Pharmaceuticals, a pharmaceutical company with inelastic demand for its specialized treatments; and Walmart, a resilient consumer staples giant and Dividend King with a strong e-commerce presence. These companies are presented as good investments for an inflationary environment due to their business models.

Baillie Gifford & Co. has increased its stake in The Home Depot, Inc. by 16.8%, acquiring an additional 21,698 shares and bringing their total holdings to 150,964 shares valued at $51.9 million. This move signals the global asset management firm's confidence in Home Depot's long-term growth potential and the home improvement sector, despite broader economic uncertainties. The investment positions Baillie Gifford as a significant shareholder, potentially influencing the retailer's strategic direction.

Nine analysts have given RLJ Lodging Trust (NYSE:RLJ) an average "Hold" rating, with a one-year average price target of $8.00. The company recently beat Q4 earnings estimates with $0.32 EPS and $328.6M revenue and set FY2026 guidance at $1.21-$1.41 EPS. Institutional investors hold 92.35% of the stock, with several increasing their positions, notably Donald Smith & CO. Inc.